ULTRASIGHTHD C31 WITH IMAGESENSE AND REMOTE VIEWER TELEMEDICINE

{0}------------------------------------------------ STI Medical Systems, LLC K110147 pg. 1 of 2 510(k) Application UltraSightHD™ C31 with ImageSense™ and Remote Viewer Telemedicine #### 510(k) Summary 5 This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21CFR 807.92 ### 1. General Information Submitter's Name and Address: STI Medical Systems, LLC 4275 Executive Square, Suite 825 La Jolla, CA 92037 APR - 8 2011 Contact Person and Telephone Number: | Rolf Wolters, Ph.D. | |-----------------------| | Senior Vice President | | rolf@sti-hawaii.com | | (808) 540-4728 | Date Prepared: January 12, 2011 ## 2. Device Information | Trade/Device Name: | UltraSightHD™ C31 Digital Colposcopy System with<br>ImageSense™ and Remote Viewer Telemedicine<br>Technologies | |----------------------------|----------------------------------------------------------------------------------------------------------------| | Classification Name: | Colposcope | | Classification Regulation: | 21 CFR § 884.1630 | | Regulatory Class: | Class II | | Product Code: | HEX | #### 3. Predicate Device(s): K090324, UltraSightHD (C30) Digital Colposcopy System with ImageSense Technology, STI Medical Systems, December 20, 2010. ### 4. Device Description: The UltraSightHD™ C31 Digital Colposcopy System with ImageSense™ and Remote Viewer Telemedicine Technologies represents a modification to the UltraSightHD (C30) Digital Colposcopy System with ImageSense Technology. It is a digital colposcope designed to acquire images of the vagina, cervix and external genitalia. It is used to diagnose abnormalities and select areas for biopsy. The illumination and optical design of the device enable the user to capture high resolution digital images. The optical subsystem is augmented by integrated image quality assessment algorithms, ensuring that focused, centered, and balanced-contrast images are acquired. Two liquid crystal displays (LCDs) provide video display and user interface information. The software includes functionality for annotating, filtering and storing the images on external PACS servers via the DICOM protocol. The ImageSense™ filters highlight certain {1}------------------------------------------------ STI Medical Systems, LLC · : · 39. 2 of 2 510(k) Applicatio UltraSightHD™ C31 with ImageSense™ and Remote Viewer Telemedicine characteristics of the captured images. The Remote Viewer Telemedicine feature enables medical personnel to view live video of an ongoing medical exam from a remote viewing station. ### 5. Indications for Use: UltraSightHD™ C31 with ImageSense™ and Remote Viewer Telemedicine is a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy. OpacityViewer™ is an ImageSense™ digital filter for displaying areas of acetowhitening. It is a tool that should NOT be used as a substitute for a thorough colposcopic evaluation. The Remote Viewer Telemedicine Technology is a software feature that enables medical personnel to view live video from the UltrasightHD during an ongoing medical exam from a remote viewing station. #### 6. Comparison of Technological Characteristics: The materials and technologies in the UltraSightHD™ C31 Digital Colposcope are suitable for their intended use and are entirely similar to those of the predicate device. The addition of the remote viewing capability allows a computer at a different location to securely connect with the device to view the same imagery visible on the colposcope. #### 7. Testing: Appropriate risk analysis-driven product testing was conducted to evaluate conformance to product specification. Successful compliance testing in accordance with IEC 60601-1 and 60601-1-2 (Safety and EMC) was conducted. The device is not patient contacting and therefore no biocompatibility testing was required. #### 8. Conclusion: The UltraSightHD™ C31 Digital Colposcopy System with ImageSense™ and Remote Viewer Telemedicine Technologies is equivalent to the UltraSightHD™ (C30) Digital Colposcopy System with ImageSense™ Technology. The indications for use, safety and efficacy, basic overall design and function, product performance, and materials used are equivalent. The addition of the remote viewer does not affect the safety and effectiveness of the device. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle. Food and Drug Administration i 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002 Rolf Wolters, Ph.D. Senior Vice President STI Medical Systems, LLC 4275 Executive Square, Suite 825 LA JOLLA CA 92037 APR - 8 2011 Re: K 110147 Trade Name: UltraSightHD™ C31 Digital Coloposcopy System with ImageSense™ OltraSignifiD ---------------------------------------------------------------------------------------------------------------------------------------------------------------- Regulation Number: 21 CFR §884.1630 Regulation Name: Colposcope Regulatory Class: II Product Code: HEX Dated: January 12, 2011 Received: January 18, 2011 Dear Dr. Wolters: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : We have reviewed your Section 510(k) premarket notification of mtent to market the indication We have reviewed your Section 510(k) premated in substantially equivant (for the indications referenced above and have develse is substantially equivated in interstate referenced above and have determined the devices narketed in interstate for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the enclosure) to legally markets breaks device Amendments, or to commerce prior to May 28, 1976, the enactment date of the Federal Food, Drug, commerce prior to May 28, 1976, the enactment with the provisions of the Federal Food, Drug, devices that have been reclassities in accordance will the proval application (PMA). and Cosmetic Act (Act) that do not require approval or a proval application of the Act. and Cosmetic Act (Act) that do not require approval or a provisions of the Act. The You may, therefore, market the device, subject to the general contralize, subjection, lis You may, therefore, market the device, subject to the general registration, listing of general controls provisions of the Act include requirements for annual registranding an general controls provisions of the Act menus and problibitions against misbranding and devices, good manufacturing practice, labelme, and evaluate information related to contract liability. adulteration. Please note: CDRH does not evaluate information related adulteration. Please note: CDRH does not evaluate unomation realing must be truthful and not misleading. warranties. We remind you, however, that device labeling must be t If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it in be and the collected and and also Eristing major regulations affec If your device is classified (see above) mo entre class if (opinisms affecting your device can be may be subject to additional controls. Exista, a Berts 800 n 898. In addit may be subject to additional controls. Existing major rogano of 888. In addition, FDA may found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In the Fede found in the Code of Federal Regulations, Title 20, 2014 - 12:00 PM the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that FDA's issuance of a substance other requirements of the Act that FDA has made a determination that your device complies with other comply that FDA has made a determination that your veries computes websites. You must comply or any Federal statutes and regulations administed by other Federal agencies. You must or any Federal statutes and regulations administration and listing and listing (21 CFR Part with all the Act's requirements, including, but not limited to: registration of me with all the Act's requirements, including, but not milled to: regulations of medical device-related {3}------------------------------------------------ ## Page 2 adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the adverse events) (21 CFR 803); good manufacturily practice rolicable, the electronic product quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electro quality systems (QS) regulation (21 CFN Far 620), and on apply of the Act); 21 CFR 1000-1050. radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please r and the states and the stime (Fices/CDRH/CDRH/CDRHOffices/ucml 15809.htm If you desire specific advice for your device offices/CDRH/Offices/ucm] I S809.htm for for for for for for for go to http://www.fda.gov/Aboutible.com/res/thics/CDFF/s) Office of Compliance. Also, please the Center for Devices and Radiological Health's (CDFH's) Officeation" (21CFR Par the Center for Devices and Radiological Health s (CDN 3) Online of Chication" (21CFR Part note the regulation entitled, "Misbranding of educere events under the MDK regulatio note the regulation entitled, "Misbranding by reference to promance in the MDR regulation (21 CFR Part 803), please go to CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of the continues. http://www.fda.gov/MedicalDcvices/Devices/Davision of Postmarket Surveillance. of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the You may obtain other general information on your responsibilities and the world. Division of Small Manufacturers, International and Consumer Assistance at its toll-free numbe Division of Small Mandracturers, 100 or at its Internet address (800) 638-2041 or (301) 796-7100 or at its Internet of Soul'Indi (800) 638-2041 or (301) 796-7100 of at its internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Hubert Lemon MD Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ K110147 UltraSightHD™ C31 Digital Colposcopy System with ImageSense™ and Device Name: Remote Viewer Telemedicine Technologies Indications For Use: UltraSightHD™ C31 with ImageSense™ and Remote Viewer Telemedicine is a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy. OpacityViewer™ is an ImageSense™ digital filter for displaying areas of acetowhitening. It is a tool that should NOT be used as a substitute for a thorough colposcopic evaluation. The Remote Viewer Telemedicine Technology is a software feature that enables medical personnel to view live video from the UltrasightHD during an ongoing medical exam from a remote viewing station. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Arry M-Wh ductive, Gastro-Renal, and 110147 Page 1 of